VTE in pregnancy

in review 6 min read Updated 2026-10-21
VTE in pregnancy

Risk ↑~10× antepartum, ~15–35× per day in the first 6 wk postpartum. Suspected PE: pregnancy-adapted YEARS + D-dimer can exclude PE in low/intermediate probability — high suspicion → empiric LMWH + imaging. Treat with weight-based LMWH ≥3 months total and ≥6 wk postpartum. No DOACs in pregnancy or breastfeeding. Prior unprovoked or oestrogen/pregnancy-related VTE → antepartum + 6 wk postpartum prophylaxis.

suspected PE — pregnancy-adapted YEARS

%%{init: {"flowchart": {"nodeSpacing": 24, "rankSpacing": 32, "wrappingWidth": 260}}}%%
flowchart TD
    A["suspected PE in pregnancy"] --> B(["haemodynamically unstable?"])
    B -->|"yes"| C["bedside echo, CTPA if feasible<br>UFH, consider reperfusion"]
    B -->|"no"| D(["DVT signs or symptoms?"])
    D -->|"yes"| E["compression US"]
    E -->|"DVT"| F["treat — no chest imaging"]
    E -->|"no DVT"| G
    D -->|"no"| G["YEARS items: DVT signs,<br>haemoptysis, PE most likely"]
    G -->|"0 items"| H["cut-off 1000 µg/L FEU"]
    G -->|"≥ 1 item"| I["cut-off 500 µg/L FEU"]
    H --> L(["D-dimer below cut-off?"])
    I --> L
    L -->|"yes"| J["PE excluded"]
    L -->|"no"| K["CTPA or V/Q"]
  • Start therapeutic LMWH while awaiting imaging if suspicion high and no bleeding contraindication
  • Thresholds are FEU — confirm local assay units (DDU values are ~half)
  • Most useful early: ARTEMIS avoided CTPA in 65% in T1 vs 32% in T3
  • Alternative validated pathway: Geneva score + D-dimer + CUS (CT-PE-Pregnancy (2018))
  • DVT in pregnancy: >80% left-sided, often isolated iliofemoral → back/buttock/flank pain; CUS negative + high suspicion → iliac Doppler or MRV — see deep vein thrombosis
high-probability PE in pregnancy

34 wk, pleuritic pain, HR 130, SpO₂ 90–95%, raised JVP, post long-haul flight → high pretest probability. Start LMWH now and image (CTPA or V/Q). D-dimer <500 does not exclude PE here. Negative leg US doesn’t exclude PE. LMWH, not a DOAC.

imaging choice

CTPAV/Q (perfusion-only possible)
foetal dosevery lowvery low (slightly higher than CTPA)
maternal breast dosehigherlower
best whenabnormal CXR, need alternative diagnosis, V/Q unavailablenormal CXR, available — often preferred (lower breast dose); TC leaves the choice to availability, expertise and patient preference
non-diagnostic ratehigher in pregnancy (contrast dilution)indeterminate results possible
  • Both far below the 50 mGy threshold for foetal harm — missing PE is the bigger risk
  • Iodinated contrast: don’t withhold; neonatal TSH check per local practice
  • Postpartum: investigate as non-pregnant. CT contrast compatible with breastfeeding; V/Q isotope may contaminate breast milk for 24–48 h (TC) — pump and discard per nuclear medicine

treatment

agenttherapeutic dose
enoxaparin1 mg/kg SC q12h (or 1.5 mg/kg daily)
dalteparin200 U/kg SC daily (or 100 U/kg q12h)
tinzaparin175 U/kg SC daily
UFH IVwhen reversal/rapid offset needed — massive PE, near delivery, high bleeding risk, CrCl <30
  • Duration: ≥3 months total and until ≥6 wk postpartum
  • Dose by weight at diagnosis (adjusting through pregnancy is controversial); once daily preferred for convenience (TC); routine anti-Xa not recommended (ASH) — consider at weight extremes, renal impairment, recurrent VTE
  • Warfarin: embryopathy T1 (6–12 wk), CNS anomalies/foetal bleeding later → avoid except mechanical valves; fine postpartum and breastfeeding
  • DOACs: cross placenta → avoid; avoid in breastfeeding
  • HIT on heparin: danaparoid first line (TC; very limited fondaparinux data in pregnancy). HIT is rare with LMWH in pregnancy — no routine platelet monitoring; with haematology/thrombosis input — see heparin-induced thrombocytopaenia
  • Massive PE: thrombolysis (alteplase doesn’t cross placenta), catheter-directed therapy, or surgical embolectomy — pregnancy is not a contraindication when life-threatening
  • IVC filter: only if acute VTE and anticoagulation contraindicated; consider retrievable filter if acute PE within 2 wk of delivery; retrieve postpartum

peripartum anticoagulation

onstop before neuraxial / planned deliveryrestart postpartum
prophylactic LMWH≥12 h≥4 h after catheter removal; 4–6 h post vaginal, 6–8 h post CS if haemostasis
therapeutic LMWH≥24 hprophylactic dose ≥12 h after delivery/epidural removal (TC), therapeutic once haemostasis secure (usually ≥24 h)
IV UFH4–6 h—
  • Planned delivery (induction/CS) if on therapeutic dose; written plan with obstetrics, anaesthesia, haematology
  • VTE within 2–4 wk of delivery → consider IV UFH peripartum; consider IVC filter
  • Spontaneous labour on LMWH → stop and assess timing with anaesthesia

thromboprophylaxis

prior VTE

prior VTEantepartum6 wk postpartum
unprovoked✓✓
oestrogen- or pregnancy-related✓✓
provoked by major transient non-hormonal factor (surgery, trauma)✗ (surveillance)✓
on long-term anticoagulationtherapeutic LMWHresume long-term agent

no prior VTE, known thrombophilia (ASH 2018)

thrombophiliaantepartum6 wk postpartum
homozygous FVL, combined thrombophilia✓✓
antithrombin deficiency✓ if family history✓ if family history
homozygous PT G20210A✓ if family history✓
protein C or S deficiency✗✓ if family history
heterozygous FVL or PT G20210A✗✗ (even with family history)
obstetric APS✓ + aspirin 81 mg✓ (6 wk)
thrombotic APStherapeutic LMWH + aspirinresume warfarin
  • Doses: enoxaparin 40 mg daily, dalteparin 5000 U daily, tinzaparin 4500 U daily; obesity (SOGC 308) → enoxaparin 60 mg daily, dalteparin 7500 U daily, tinzaparin 75 U/kg daily; TC: ≥100–120 kg → intermediate dose (enoxaparin 40 mg BID or 80 mg OD, dalteparin 5000 U BID or 10 000 U OD, tinzaparin 10 000 U OD)
  • No anti-Xa monitoring on prophylactic doses
  • Prior oestrogen-related VTE: ~5–10% recurrence risk in pregnancy without prophylaxis
  • Postpartum prophylaxis also for CS with risk factors (preeclampsia + FGR, BMI >30, emergency CS, multiples, smoking) — obstetric risk tools
  • Don’t routinely test for thrombophilia — only if result changes management; protein S falls in normal pregnancy. See hereditary thrombophilia, antiphospholipid syndrome
contraception with every anticoagulant prescription

Avoid oestrogen-containing methods after VTE. Options: LNG-IUD, copper IUD, etonogestrel implant, progestin-only pill, tubal ligation.


evidence

Prepared 2026-10-21. Not yet verified — check every number against the sources.

Key references

+5 more sources

Suggest a correction VTE in pregnancy